When I became interested in drug development almost 2 decades ago, I just didn’t get it: why was it that gene-centric biotech was seen as ...

ALN-TTR02 for the treatment of TTR amyloidosis is the most advanced RNAi Therapeutic in clinical development and has been carrying the tor...

Alnylam this morning reported top-line results from a phase II study of their first clinical candidate based on the GalNAc-siRNA conjugat...

( For a discussion of the phase I results, see here ). Alnylam is about to reveal results from its phase I study with ALN-TTR01 for the tr...